Hydroxyurea Use in Patients with Sickle Cell Anemia

Project Title Hydroxyurea Use in Patients with Sickle Cell Anemia
Date Posted
Tuesday, January 7, 2020
Project ID
cder_mpl1r_wp071, cder_mpl1r_wp078

The purpose of this request was to characterize hydroxyurea use among members with sickle cell anemia (SCA). Data from January 1, 2000 to September 30, 2015 from 17 Data Partners contributing to the Sentinel Distributed Database (SDD) were included in these reports. This request was distributed on February 28, 2018. This request contains two reports.

Report 1 estimated the number patients with SCA, the number of SCA patients who were dispensed hydroxyurea, and the average number of hospitalizations and emergency department visits per person-year among those patients in the SDD. 

Report 2 examines utilization patterns of hydroxyurea among patients with SCA in the SDD. 

Medical Product
Health Outcome
sickle cell anemia
use by indication
Population / Cohort
All individuals
Time Period
January 1, 2000 - September 30, 2015
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
Scroll to Top